Pancragen Preclinical

What It Is

Pancragen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Trp (L-lysyl-L-glutamyl-L-aspartyl-L-tryptophan), abbreviated KEDW, and a molecular weight of approximately 547 daltons. It belongs to the family of "short peptide bioregulators" developed and systematically characterized by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology over the period 1990 to present. Each Khavinson peptide is targeted to a specific organ or tissue system — Epithalon (AEDG) to the pineal gland and aging, Thymalin / Thymogen to thymus and immune function, Cortexin / Pinealon (EDR) to brain and cognition, Vilon (KE) to thymus, Bronchogen (AEDL) to lung — and Pancragen is positioned as the pancreas-specific member of the series.

The Khavinson framework emerged from mid-1970s work in which his group fractionated tissue-specific peptide extracts from bovine organs (cerebral cortex, thymus, prostate, pineal) and observed tissue-trophic effects in aged and diseased animal models. Over the subsequent decades, progressively smaller active fragments were identified from each extract until "minimal pharmacologically active" dipeptides, tripeptides, and tetrapeptides were isolated. Pancragen is the synthetic version of the active tetrapeptide identified in pancreatic tissue extracts.

Pancreas-specific clinical indications within the Russian framework have included: age-related decline in pancreatic endocrine function (reduced insulin secretion, glucose intolerance progressing toward type 2 diabetes), early-stage type 2 diabetes as adjunct to standard care, chronic pancreatitis with exocrine insufficiency, and supportive care during pancreatic surgery recovery. Dosing follows the broader Khavinson "pulse course" framework — short discrete treatment courses (typically 10–20 days) administered 2–3 times per year, with the rationale that tissue-level gene-expression changes persist beyond plasma clearance.

In Russia, Pancragen-branded products are registered as dietary supplements / biologically active food additives (БАД), primarily through Peptides Ltd. and related Khavinson-group companies. They are not registered as pharmaceutical drugs with proprietary NDA-equivalent dossiers under the Russian pharmaceutical regulatory system. In the United States, Pancragen is not FDA-approved for any indication and is not eligible for 503A or 503B compounding because no FDA-approved reference product exists for the defined sequence. Community use is supplied through research-chemical vendors; quality and verification practices vary substantially among suppliers.

Mechanism of Action

Pancragen's proposed mechanism centers on the same small-peptide nuclear-regulatory framework Khavinson applies to the other short-peptide bioregulators. The specificity to pancreatic tissue is proposed to arise from tissue-specific chromatin accessibility patterns rather than a conventional receptor interaction.

• Small peptide size enables direct cellular entry — At ~547 Da, Pancragen is small enough to diffuse across cellular and nuclear membranes without active transport. This is the mechanistically distinguishing feature that Khavinson's framework emphasizes vs receptor-mediated peptide signaling.
• Chromatin and DNA-sequence interaction — Khavinson's group has proposed — and in vitro DNA-binding studies support — that short peptides bind AT-rich regions of double-stranded DNA, modulating transcription of specific gene sets via changes in chromatin accessibility. For Pancragen, the target gene sets are proposed to include insulin (INS), PDX-1 (master β-cell transcription factor), GLUT-2 (glucose transporter), glucokinase (GCK), and digestive enzyme genes (amylase, lipase, trypsinogen).
• β-cell gene expression normalization — Preclinical data suggests Pancragen restores INS and PDX-1 expression in β-cell lines exposed to glucolipotoxic stress — modeling the β-cell dysfunction of early type 2 diabetes. This transcriptional support is proposed as the primary anti-diabetic mechanism.
• β-cell anti-apoptotic signaling — Reduces caspase-3 activation and TUNEL-positive apoptotic β-cells in culture and streptozotocin-induced diabetes models. Preservation of β-cell mass is a clinically meaningful target for type 2 diabetes progression.
• Glucose-stimulated insulin secretion (GSIS) — Restores normal biphasic GSIS in β-cells with reduced function, improving the postprandial insulin response that is characteristically blunted in early diabetes.
• Exocrine pancreatic support — Upregulates digestive enzyme gene expression (amylase, lipase, trypsinogen, chymotrypsinogen) in acinar cells — relevant to chronic pancreatitis-associated exocrine insufficiency.
• Anti-inflammatory signaling — Reduces pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in pancreatic tissue under metabolic or inflammatory stress, potentially relevant to autoimmune insulitis and chronic pancreatitis.
• Antioxidant effects — Supports endogenous antioxidant capacity (glutathione peroxidase, superoxide dismutase) in pancreatic cells, consistent with the broader Khavinson-framework claim of tissue-trophic protection.
• Pleiotropic vs receptor-specific — Unlike GLP-1 agonists (which activate a defined Gαs-coupled GPCR) or insulin (which engages the insulin receptor tyrosine kinase), Pancragen's proposed mechanism is transcriptional-regulatory and broadly pleiotropic. This is both its theoretical strength (multi-target effect) and the reason mainstream diabetes pharmacology has been slow to engage the framework — it is harder to validate with receptor-pharmacology methods.
• Short-peptide "epigenetic" framing — The Khavinson group increasingly describes the bioregulator peptides as "epigenetic" regulators: modulators of chromatin accessibility and gene expression programs rather than direct transcription factors. This framing is a 2015–2023 evolution of the earlier "signal peptide" language.

What the Research Shows

Pancragen's evidence base is Russian-centric and concentrated in the Khavinson group, consistent with the pattern of the other Khavinson bioregulators.

• Streptozotocin-diabetes rodent model — Multiple Khavinson-group papers report that Pancragen (oral or SubQ) improves glucose tolerance, preserves β-cell mass, and increases serum insulin levels in streptozotocin-induced diabetes models compared with diabetic controls.
• β-cell culture apoptosis protection — In vitro β-cell line studies (MIN6, INS-1E) show reduced apoptosis markers under glucolipotoxic stress conditions when Pancragen is present in culture media.
• PDX-1 and INS gene upregulation — Quantitative RT-PCR in cultured β-cells and pancreatic tissue from treated animals shows increased transcription of insulin and PDX-1 genes after Pancragen exposure.
• Age-related pancreatic function studies (Linkova, Khavinson) — Russian clinical and cell-culture studies examining Pancragen's effects on age-associated decline in pancreatic secretory capacity.
• Type 2 diabetes clinical reports — Russian-language case series describing improved glycemic markers (fasting glucose, HbA1c reductions) and reduced insulin requirements in early-stage T2D patients receiving Pancragen as adjunct to standard care. Methodologically open-label or small-controlled; no Western-standard RCT.
• Chronic pancreatitis exocrine support — Reports describing improved digestive symptoms and pancreatic enzyme markers in chronic pancreatitis patients treated within the Khavinson bioregulator framework.
• Khavinson-framework comprehensive reviews — Multiple authoritative Khavinson-authored reviews place Pancragen within the broader bioregulator landscape alongside Epithalon, Thymalin, Pinealon, and related peptides (Neuro Endocrinology Letters 2002; Biogerontology 2010; Molecules 2021).
• Peptide-DNA binding studies (Kolchina, Khavinson; Nucleic Acids Res 2019) — Systematic search for structural motifs of peptide binding to double-stranded DNA — the mechanistic underpinning of the Pancragen framework as applied to pancreatic gene expression.
• Independent replication gap — Outside the Khavinson group and affiliated St. Petersburg laboratories, independent replication of Pancragen's pancreas-specific effects is minimal. The peptide-DNA-binding framework itself is the subject of ongoing methodological debate in mainstream molecular biology.
• No Phase 2 or Phase 3 Western RCT — The evidence gap separating Pancragen from approved diabetes pharmacotherapies (metformin, GLP-1 agonists, SGLT2 inhibitors, insulin, pramlintide) is the critical honest framing.

Human Data

Human evidence for Pancragen is concentrated in Russian clinical reports and case series:

• Russian type 2 diabetes adjunct case series — Open-label reports describing improved fasting glucose, postprandial glucose, HbA1c, and reduced insulin / sulfonylurea requirements in early-stage T2D patients on Pancragen as adjunct.
• Chronic pancreatitis clinical reports — Russian case series describing improved digestive symptoms, pancreatic enzyme replacement reduction, and inflammatory marker improvement with Pancragen courses.
• Age-related metabolic decline — Reports of glucose tolerance improvement in elderly patients without frank diabetes — the "pre-diabetic" or age-related metabolic frailty phenotype.
• Post-surgical pancreatic recovery — Anecdotal reports of Pancragen use during recovery from partial pancreatectomy or pancreatic trauma.
• Longevity-framework community use — Users in the longevity / Khavinson-peptide community stack Pancragen with Epithalon, Thymalin, and other bioregulators; anecdotal reports of improved glycemic markers and reduced insulin resistance over cyclical course protocols.
• No published Phase 2 or Phase 3 RCT — For any indication at FDA/EMA regulatory quality standards.
• Small Russian controlled trials — Small Khavinson-group controlled studies have been published in Russian gerontology and endocrinology journals; translation and methodological transparency are limited.
• Safety experience — Decades of Russian-framework use in the dietary-supplement regulatory category have not surfaced significant safety signals at labeled doses.

The pattern mirrors other Khavinson peptides: substantial Russian clinical experience and preclinical mechanism, limited Western methodological replication, no FDA-quality Phase 3 program. Users choosing Pancragen are implicitly accepting this evidence profile.

Dosing from the Literature

Dosing follows the Khavinson "pulse course" framework — short discrete courses, not chronic daily dosing.

Reconstitution & Storage

Pancragen is typically supplied as lyophilized tetrapeptide powder in 10 mg or 20 mg vials, or as oral capsules (Khavinson-branded Russian products typically use oral capsule formulation).

• Reconstitution (for SubQ) — Bacteriostatic water down vial wall at 45°, swirl gently, do not shake.
• Oral dosing — Preferred route in Russian practice. Take on empty stomach; some protocols specify sublingual hold for 1–2 minutes before swallowing.
• Storage — Lyophilized: refrigerated 2–8°C preferred; room temp acceptable short-term. Reconstituted: 2–8°C, use within 21–28 days. Do not freeze reconstituted peptide.
• Timing — Morning dosing most common; no clear evidence for chronobiologic optimization.
• Inspection — Reconstituted solution clear and colorless; discard if cloudy.

→ Use the Kalios Peptide Calculator for dose conversions

Side Effects & Risks

Pancragen has one of the cleaner safety records in the Khavinson bioregulator family, consistent with decades of Russian use in the dietary-supplement framework.

• Generally well-tolerated — Russian clinical and community experience reports no consistent adverse signal at framework doses.
• Mild GI upset (oral) — Occasional nausea or mild GI symptoms with oral dosing; usually transient and resolves with continued use.
• Injection site reactions (SubQ) — Mild and self-limiting; typical for any SubQ peptide.
• Hypoglycemia risk (theoretical) — Given the proposed insulin-secretion-enhancing mechanism, caution with concurrent insulin, sulfonylureas, or meglitinides is prudent. Monitor glucose if combined.
• Drug interactions — Minimal documented. Theoretical interactions with all diabetes medications via shared target pathway.
• No documented cardiovascular signal — Across Khavinson-framework clinical experience.
• No documented hepatotoxicity — Across Khavinson-framework clinical experience.
• No documented hematologic signal — Across Khavinson-framework clinical experience.
• Pregnancy / lactation — Not studied; avoid.
• Pediatric use — Not studied; avoid outside clinician-supervised specialty practice.
• Cancer concerns (theoretical) — No documented pro-cancer signal. Khavinson's framework positions bioregulators as broadly protective rather than growth-promoting; independent characterization of pancreatic-cancer-cell-line effects is limited.
• Purity / sourcing — Tetrapeptide synthesis is straightforward; gross purity problems are uncommon. Third-party HPLC and mass-spec COAs are the operational floor for research-chemical supply.
• WADA status — Not specifically named on the Prohibited List as of 2026.
• FDA status — Not approved; not scheduled. Research-chemical supply in the US.

Bloodwork & Monitoring

Pancragen's target system (pancreas — endocrine and exocrine) provides clear laboratory surveillance targets.

• Fasting glucose, HbA1c — Baseline and after course completion. Primary outcome metrics for endocrine pancreatic function.
• Fasting insulin, C-peptide — β-cell function markers. HOMA-IR and HOMA-β calculations from fasting insulin and glucose inform insulin resistance and secretion.
• OGTT (if pre-diabetic or age-related metabolic decline) — Oral glucose tolerance test captures postprandial β-cell response that fasting values miss.
• Lipid panel — Diabetes-associated dyslipidemia context.
• Amylase, lipase — Exocrine pancreatic markers; baseline and during/after course if chronic pancreatitis is the indication.
• Stool elastase — Exocrine pancreatic insufficiency marker; baseline for chronic pancreatitis patients.
• Baseline CMP / CBC — Standard pre-treatment characterization.
• CRP / inflammatory markers — Track anti-inflammatory claim (primarily for chronic pancreatitis context).
• Weight, waist circumference — Metabolic phenotype context; diabetes-prevention framing.
• Glucose self-monitoring — Home glucose monitoring during course, especially if combined with insulin or sulfonylureas.

Supportive Nutrition & Lifestyle

Pancreatic function and glucose metabolism depend heavily on nutritional, body-composition, and activity inputs. Pancragen sits on top of these foundations, not as a substitute.

• Carbohydrate quality and quantity — Primary lever for glycemic control. Replacing refined carbohydrates and added sugars with whole-food sources (vegetables, legumes, intact grains) reduces postprandial glucose excursions and β-cell workload. More impactful than any peptide.
• Resistance training (2–4x per week) — Skeletal muscle is the largest glucose-disposal organ. Resistance training increases insulin sensitivity independent of weight loss. The single best-evidenced non-pharmacological intervention for insulin resistance.
• Aerobic exercise — Post-meal walks (15–30 minutes after meals) meaningfully blunt postprandial glucose excursions. A simple, high-leverage behavioral intervention.
• Body weight and visceral adiposity — Modest weight loss (5–10%) in overweight / obese populations dramatically reduces insulin resistance and β-cell demand. Pancragen's claimed β-cell protective effects are most mechanistically coherent in the context of active weight management.
• Sleep quality — Sleep deprivation acutely induces insulin resistance. 7–9 hours of quality sleep is foundational for glucose metabolism.
• Magnesium (300–400 mg/day) — Deficiency is associated with insulin resistance; repletion improves glycemic markers in deficient populations.
• Vitamin D (40–60 ng/mL) — Low vitamin D associated with diabetes risk; correction is modest but reasonable.
• Chromium (200–400 µg/day) — Cofactor for insulin signaling; evidence modest but effect plausible in deficient populations.
• Omega-3 (EPA/DHA 2–3 g/day) — Anti-inflammatory; supports β-cell survival in preclinical models.
• Alpha-lipoic acid (600 mg/day) — Antioxidant with insulin-sensitizing effects in diabetic populations.
• Berberine (500 mg 2–3x daily) — AMPK activator with metformin-like glycemic effects. Used in natural-medicine protocols.
• Things to avoid — Chronic alcohol (pancreatic toxicity), smoking (β-cell dysfunction), chronic glucocorticoid use where avoidable (insulin resistance), ultra-processed food.
• Metformin if indicated — If type 2 diabetes is diagnosed, metformin remains the evidence-based first-line pharmacotherapy and should not be substituted with Pancragen alone.

Practical User Notes

• Course-based, not continuous — Follow the Khavinson framework. 10–20 day courses, 2–3x per year. Chronic daily dosing is not the intended pattern.
• Oral is the canonical route — Russian practice is oral. Community SubQ protocols are alternatives, not replacements. Pancragen's small size supports oral absorption.
• Morning dosing, empty stomach — Consistent with Khavinson framework practice. Some users hold sublingually 1–2 minutes before swallowing.
• Do not stop standard care — If currently on metformin, GLP-1 agonist, SGLT2 inhibitor, insulin, or sulfonylurea, do not discontinue based on Pancragen use. Pancragen is adjunct, not substitute.
• Glucose monitoring during course — Home glucose monitoring during course is reasonable, especially if combined with insulin or sulfonylureas (theoretical hypoglycemia risk).
• Track outcomes objectively — Fasting glucose, HbA1c, fasting insulin pre- and post-course. Subjective report is unreliable for glycemic outcomes.
• Alternate with other Khavinson peptides — Canonical framework protocol. Pancragen, then Epithalon, then Thymalin, etc. — rotating through the tissue-specific bioregulators over the year.
• Sourcing matters — Russian pharmacy imports from Khavinson-affiliated manufacturers are the quality benchmark. Research-chemical vendors require third-party HPLC and mass-spec COAs at minimum.
• Expectations — Subtle effects at best. If Pancragen works, signals may include modest fasting glucose improvement, reduced postprandial glucose excursions, and improved digestive function if the indication is exocrine insufficiency. Do not expect transformation.
• Red flags to stop — Unexplained hypoglycemia, new GI symptoms that persist, any new unexpected symptom.
• Do not substitute for GLP-1 agonist therapy — Semaglutide, tirzepatide, and other GLP-1 agonists have rigorous Phase 3 weight-loss and glycemic data. Pancragen has no comparable data. Never discontinue evidence-based therapy to "try" Pancragen.
• Patient population fit — Most mechanistically coherent in the Khavinson-framework target population: age-related metabolic decline, early pre-diabetes, or chronic pancreatitis with exocrine insufficiency as adjunct to standard care.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Pancragen often also look at these:

Next Steps

Key References

1. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12370707. (Comprehensive Khavinson peptide framework monograph; includes Pancragen.)
2. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
3. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997.
4. Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger; Basel; 2005. (Monograph; framework reference for all Khavinson peptides including Pancragen.)
5. Khavinson V, Popovich I, Linkova N, Mironova E, Ilina A. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834146.
6. Kolchina N, Khavinson V, Linkova N, Yakutseni P, Petukhov M, Morozova E, Ashapkin V. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Res. 2019;47(20):10553-10563. PMID: 31584079.
7. Linkova NS, Drobintseva AO, Orlova OA, et al. Peptide regulation of beta-cell function during aging. Adv Gerontol. 2015;28(3):478-484.
8. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic Mechanisms of Peptidergic Regulation of Gene Expression during Aging of Human Cells. Biochemistry (Mosc). 2015;80(3):310-322. PMID: 25761684.
9. Khavinson VK, Kuznik BI, Lin'kova NS, et al. Peptide Medicines: Past, Present, Future. Clin Med (Russian Journal). 2022;100(1):5-13. (Comprehensive framework review placing Pancragen in broader bioregulator context.)
10. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of aging: methodology and evidence. Bull Exp Biol Med. 2022.
11. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation, Proliferation, and Apoptosis. Adv Gerontol. 2020;10(2):98-106.
12. Khavinson VKh, Kuznik BI, Trofimova SV, Lin'kova NS. Cortexin and its short peptides AEDG and EDR modulate gene expression of proteins in pathogenesis of Alzheimer's disease. Biomed Khim. 2020. (Parallel framework evidence for the Khavinson short-peptide gene-expression paradigm.)
13. Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Int J Mol Sci. 2020;21(2):609. PMID: 31963526.
14. Khavinson VK. Peptide regulation of ageing: 40 years of research. Adv Gerontol. 2020. (Retrospective review of the Khavinson peptide program; Pancragen placed in context.)
15. American Diabetes Association. Standards of Medical Care in Diabetes 2024 / 2025. Diabetes Care. 2024;47(Suppl 1). (Context reference: FDA-approved standard-of-care diabetes pharmacotherapy landscape.)